Strain Name:

C57BL/6-Tg(IghelMD4)4Ccg/J

Stock Number:

002595

Availability:

Repository- Live

Description

Strain Information

Type Mutant Strain; Transgenic;
Additional information on Genetically Engineered Mutant Mice.
Mating SystemInbred x Hemizygote         (Female x Male)
Specieslaboratory mouse
GenerationN?+28 (22-JAN-08)
 
Donating Investigator Christopher Goodnow,   Stanford University School of Medicine

Appearance
black
Related Genotype: a/a

Description
Cells from mice carrying the IghelMD4 transgene recognize hen egg lysozyme. More than 90% of B-cells in the spleen are derived from the transgene (a allotype) and are predominantly IgM and IgD. This strain may be used to study B-cell selection.

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(IghelMD4)4Ccg allele
006345   NOD.B6-Tg(IghelMD4)4Ccg/DvsJ
006608   NOD.Cg-Igh-6tm1Cgn Tg(IghelMD4)4Ccg/DvsJ
View Strains carrying   Tg(IghelMD4)4Ccg     (2 strains)

Strains carrying other alleles of Igh
007594   B6.129P2-Ptrpca Ightm1Mnz/J
008332   C.129S1-Ightm1Janz/J
007775   CBy.129P2(B6)-Ightm1Mnz/J
003395   CD1-Tg(Igh-HOX11)11Idd/J
View Strains carrying other alleles of Igh     (4 strains)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms
      assigned by genotype

Tg(IghelMD4)4Ccg/0

        involves: C57BL/6
  • immune system phenotype
  • abnormal B cell activation (MGI Ref ID J:73608)
    • B cells become activated when cultured with HEL protein and CD4 T cells from Tg(TcrHEL3A9)1Mmd transgenic mice
    • B cells in this culture quickly upregulate CD44 and CD86
    • by 48 hours in culture, B cells are greatly enlarged as they undergo blastogenesis
    • B cells cultured without the T cells initially upregulate activation markers but then die
    • when HEL peptide is used in culture, some B cells increase expression of activation markers but do not form large blast cells
  • decreased pre-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background
  • decreased pro-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background
  • hematopoietic system phenotype
  • abnormal B cell activation (MGI Ref ID J:73608)
    • B cells become activated when cultured with HEL protein and CD4 T cells from Tg(TcrHEL3A9)1Mmd transgenic mice
    • B cells in this culture quickly upregulate CD44 and CD86
    • by 48 hours in culture, B cells are greatly enlarged as they undergo blastogenesis
    • B cells cultured without the T cells initially upregulate activation markers but then die
    • when HEL peptide is used in culture, some B cells increase expression of activation markers but do not form large blast cells
  • decreased pre-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background
  • decreased pro-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background

Tg(IghelMD4)4Ccg/0

        C57BL/6-Tg(IghelMD4)4Ccg
  • immune system phenotype
  • abnormal B cell morphology (MGI Ref ID J:78308)
    • over 90% of B cells express immunoglobulin that has a high affinity for hen egg lysozyme antigen (HEL)
    • most peripheral B cells express the transgenic immunoglobulin (Ig) that binds hen egg lysozyme peptide (HEL) with a high affinity
    • the few B cells expressing endogenous Ig in the spleen express high levels of IgM with little to no levels of IgD compared to splenic B cells from wild-type mice that are IgMlow IgDhigh
    • abnormal immature B cell morphology (MGI Ref ID J:109923)
      • there are reduced numbers of immature B cells bearing transgenic IgM in the bone marrow
      • increased immature B cell number (MGI Ref ID J:132538)
        • three quarters of the B cells in the spleen are immature as indicated by the IgMhi IgDhi surface markers
        • three quarters of the B cells in the spleen are immature as indicated by the IgMhi IgDhi surface markers
    • abnormal mature B cell morphology (MGI Ref ID J:89156)
      • 98% of the B cells express the transgenic antibody that is specific for hen egg lysozyme (HEL)
      • 94% of these B cells retain the ability to bind HEL protein
      • there is an increased percentage of mature B cells in the bone marrow
      • abnormal B-2 B cell morphology (MGI Ref ID J:132538)
        • all of the B cells found in the peritoneal cavity are of the B-2 lineage as determined by B220hi CD5lowexpression
      • abnormal germinal center B cell morphology (MGI Ref ID J:109923)
        • B cells expressing the transgenic Ig are absent from the germinal center of the spleen and lymph nodes
    • abnormal plasma cell morphology (MGI Ref ID J:109923)
      • plasma cells bearing endogenous Ig outnumber plasma cells bearing the transgenic Ig
    • abnormal pro-B cell morphology (MGI Ref ID J:109923)
      • there are reduced numbers of pro-B cells bearing transgenic IgM in the bone marrow
  • increased IgG2b level (MGI Ref ID J:132538)
    • there are low levels of anti-HEL IgG2b in the sera of unimmunized mice
  • increased IgM level (MGI Ref ID J:132538)
    • there are high levels of anti-HEL IgM in the sera of unimmunized mice
    • there are high levels of anti-HEL IgM in the sera of unimmunized mice
  • hematopoietic system phenotype
  • abnormal B cell morphology (MGI Ref ID J:78308)
    • over 90% of B cells express immunoglobulin that has a high affinity for hen egg lysozyme antigen (HEL)
    • most peripheral B cells express the transgenic immunoglobulin (Ig) that binds hen egg lysozyme peptide (HEL) with a high affinity
    • the few B cells expressing endogenous Ig in the spleen express high levels of IgM with little to no levels of IgD compared to splenic B cells from wild-type mice that are IgMlow IgDhigh
    • abnormal immature B cell morphology (MGI Ref ID J:109923)
      • there are reduced numbers of immature B cells bearing transgenic IgM in the bone marrow
      • increased immature B cell number (MGI Ref ID J:132538)
        • three quarters of the B cells in the spleen are immature as indicated by the IgMhi IgDhi surface markers
        • three quarters of the B cells in the spleen are immature as indicated by the IgMhi IgDhi surface markers
    • abnormal mature B cell morphology (MGI Ref ID J:89156)
      • 98% of the B cells express the transgenic antibody that is specific for hen egg lysozyme (HEL)
      • 94% of these B cells retain the ability to bind HEL protein
      • there is an increased percentage of mature B cells in the bone marrow
      • abnormal B-2 B cell morphology (MGI Ref ID J:132538)
        • all of the B cells found in the peritoneal cavity are of the B-2 lineage as determined by B220hi CD5lowexpression
      • abnormal germinal center B cell morphology (MGI Ref ID J:109923)
        • B cells expressing the transgenic Ig are absent from the germinal center of the spleen and lymph nodes
    • abnormal plasma cell morphology (MGI Ref ID J:109923)
      • plasma cells bearing endogenous Ig outnumber plasma cells bearing the transgenic Ig
    • abnormal pro-B cell morphology (MGI Ref ID J:109923)
      • there are reduced numbers of pro-B cells bearing transgenic IgM in the bone marrow

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

Tg(IghelMD4)4Ccg/0

        involves: C3H/HeJ * C57BL/6
  • hematopoietic system phenotype
  • decreased pre-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background
  • decreased pro-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background
  • immune system phenotype
  • decreased pre-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background
  • decreased pro-B cell number (MGI Ref ID J:115059)
    • bone marrow contains fewer combined numbers of combined pro-pre B cells than on a B6 background
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Igh related

Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers

Igk related
CD Antigens, Antigen Receptors, and Histocompatibility Markers

Genes & Alleles

Gene & Allele Information

Allele Symbol Tg(IghelMD4)4Ccg
Allele Name transgene insertion 4, Christopher C Goodnow
Allele Type Transgenic (random, expressed)
Common Name(s) HELmuMT; Hel-Ig; Ig-transgenic; IgHEL; MD-3; MD4; MD4 HEL Ig; MD4 Ig BCR Tg; MD4-RAG;
Mutation Made By Christopher Goodnow,   Stanford University School of Medicine
Strain of OriginC57BL/6
Expressed Gene Igh, immunoglobulin heavy chain complex, mouse, laboratory
Expressed Gene Igk, immunoglobulin kappa chain complex, mouse, laboratory
Molecular Note The hybridoma HyHEL10 produces an antibody with high affinity for hen egg lysozyme. Genomic clones encoding HyHEL10 immunoglobulin heavy and light chains were used for this construct. The gamma1-constant region of the heavy chain was replaced by a segment containing the mu and delta constant region genes derived from BALB/c mice. The light and heavy chains were co-injected into C57BL/6 eggs. Five lines, MD3-MD7, that carried multiple copies of the transgene construct were created. The MD4 line had thehighest expression of the transgene and was propogated for further studies. Mice carrying this transgene had high serum titers of anti-lysozyme antibodies. [MGI Ref ID J:78308]

Genotyping

Genotyping Information

Genotyping Protocols

Tg(IghelMD4)4Ccg, STD PCR, vers. 1

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Mason DY; Jones M; Goodnow CC. 1992. Development and follicular localization of tolerant B lymphocytes in lysozyme/anti-lysozyme IgM/IgD transgenic mice. Int Immunol 4(2):163-75. [PubMed: 1622894]  [MGI Ref ID J:109923]

Additional References

Gerth AJ; Lin L; Neurath MF; Glimcher LH; Peng SL. 2004. An innate cell-mediated, murine ulcerative colitis-like syndrome in the absence of nuclear factor of activated T cells. Gastroenterology 126(4):1115-21. [PubMed: 15057750]  [MGI Ref ID J:93475]

Goodnow CC; Crosbie J; Adelstein S; Lavoie TB; Smith-Gill SJ; Brink RA; Pritchard-Briscoe H; Wotherspoon JS; Loblay RH; Raphael K; et al.. 1988. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334(6184):676-82. [PubMed: 3261841]  [MGI Ref ID J:78308]

Tg(IghelMD4)4Ccg related

Akkaraju S; Ho WY; Leong D; Canaan K; Davis MM; Goodnow CC. 1997. A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis. Immunity 7(2):255-71. [PubMed: 9285410]  [MGI Ref ID J:78309]

Arana E; Vehlow A; Harwood NE; Vigorito E; Henderson R; Turner M; Tybulewicz VL; Batista FD. 2008. Activation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunological-synapse formation. Immunity 28(1):88-99. [PubMed: 18191593]  [MGI Ref ID J:131150]

Ashour HM; Niederkorn JY. 2006. Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation. J Immunol 176(10):5950-7. [PubMed: 16670303]  [MGI Ref ID J:131707]

Bai L; Chen Y; He Y; Dai X; Lin X; Wen R; Wang D. 2007. Phospholipase Cgamma2 contributes to light-chain gene activation and receptor editing. Mol Cell Biol 27(17):5957-67. [PubMed: 17591700]  [MGI Ref ID J:125007]

Barrington RA; Borde M; Rao A; Carroll MC. 2006. Involvement of NFAT1 in B cell self-tolerance. J Immunol 177(3):1510-5. [PubMed: 16849457]  [MGI Ref ID J:137979]

Barrington RA; Zhang M; Zhong X; Jonsson H; Holodick N; Cherukuri A; Pierce SK; Rothstein TL; Carroll MC. 2005. CD21/CD19 coreceptor signaling promotes B cell survival during primary immune responses. J Immunol 175(5):2859-67. [PubMed: 16116172]  [MGI Ref ID J:113242]

Bemark M; Sale JE; Kim HJ; Berek C; Cosgrove RA; Neuberger MS. 2000. Somatic hypermutation in the absence of DNA-dependent protein kinase catalytic subunit (DNA-PK(cs)) or recombination-activating gene (RAG)1 activity J Exp Med 192(10):1509-14. [PubMed: 11085752]  [MGI Ref ID J:65886]

Blery M; Tze L; Miosge LA; Jun JE; Goodnow CC. 2006. Essential role of membrane cholesterol in accelerated BCR internalization and uncoupling from NF-kappa B in B cell clonal anergy. J Exp Med 203(7):1773-83. [PubMed: 16801401]  [MGI Ref ID J:124402]

Bour-Jordan H; Salomon BL; Thompson HL; Santos R; Abbas AK; Bluestone JA. 2007. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol 179(2):1004-12. [PubMed: 17617592]  [MGI Ref ID J:131077]

Carrasco YR; Batista FD. 2006. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. EMBO J 25(4):889-99. [PubMed: 16456548]  [MGI Ref ID J:106020]

Chackerian B; Durfee MR; Schiller JT. 2008. Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 180(9):5816-25. [PubMed: 18424700]  [MGI Ref ID J:134321]

Cinamon G; Matloubian M; Lesneski MJ; Xu Y; Low C; Lu T; Proia RL; Cyster JG. 2004. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 5(7):713-20. [PubMed: 15184895]  [MGI Ref ID J:91161]

Cook MC; Basten A; Fazekas de St Groth B. 1997. Outer periarteriolar lymphoid sheath arrest and subsequent differentiation of both naive and tolerant immunoglobulin transgenic B cells is determined by B cell receptor occupancy. J Exp Med 186(5):631-43. [PubMed: 9271579]  [MGI Ref ID J:132748]

Cornall RJ; Cheng AM; Pawson T; Goodnow CC. 2000. Role of Syk in B-cell development and antigen-receptor signaling. Proc Natl Acad Sci U S A 97(4):1713-8. [PubMed: 10677523]  [MGI Ref ID J:60647]

Deng J; Dekruyff RH; Freeman GJ; Umetsu DT; Levy S. 2002. Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses. Int Immunol 14(5):513-23. [PubMed: 11978781]  [MGI Ref ID J:113522]

Depoil D; Fleire S; Treanor BL; Weber M; Harwood NE; Marchbank KL; Tybulewicz VL; Batista FD. 2008. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 9(1):63-72. [PubMed: 18059271]  [MGI Ref ID J:130478]

Ekland EH; Forster R; Lipp M; Cyster JG. 2004. Requirements for follicular exclusion and competitive elimination of autoantigen-binding B cells. J Immunol 172(8):4700-8. [PubMed: 15067045]  [MGI Ref ID J:89130]

Enders A; Bouillet P; Puthalakath H; Xu Y; Tarlinton DM; Strasser A. 2003. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 198(7):1119-26. [PubMed: 14517273]  [MGI Ref ID J:86002]

Ferry H; Crockford TL; Silver K; Rust N; Goodnow CC; Cornall RJ. 2005. Analysis of Lyn/CD22 double-deficient B cells in vivo demonstrates Lyn- and CD22-independent pathways affecting BCR regulation and B cell survival. Eur J Immunol 35(12):3655-63. [PubMed: 16278813]  [MGI Ref ID J:113739]

Fillatreau S; Gray D. 2003. T cell accumulation in B cell follicles is regulated by dendritic cells and is independent of B cell activation. J Exp Med 197(2):195-206. [PubMed: 12538659]  [MGI Ref ID J:124822]

Foote LC; Evans JW; Cifuni JM; Siracusa MC; Monteforte GM; McCole JL; D'Orazio CC; Hastings WD; Rothstein TL. 2004. Interleukin-4 produces a breakdown of tolerance in vivo with autoantibody formation and tissue damage. Autoimmunity 37(8):569-77. [PubMed: 15763919]  [MGI Ref ID J:128253]

Gerth AJ; Lin L; Neurath MF; Glimcher LH; Peng SL. 2004. An innate cell-mediated, murine ulcerative colitis-like syndrome in the absence of nuclear factor of activated T cells. Gastroenterology 126(4):1115-21. [PubMed: 15057750]  [MGI Ref ID J:93475]

Goodnow CC; Crosbie J; Adelstein S; Lavoie TB; Smith-Gill SJ; Brink RA; Pritchard-Briscoe H; Wotherspoon JS; Loblay RH; Raphael K; et al.. 1988. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334(6184):676-82. [PubMed: 3261841]  [MGI Ref ID J:78308]

Grewal PK; Boton M; Ramirez K; Collins BE; Saito A; Green RS; Ohtsubo K; Chui D; Marth JD. 2006. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol Cell Biol 26(13):4970-81. [PubMed: 16782884]  [MGI Ref ID J:110325]

Harris DP; Goodrich S; Gerth AJ; Peng SL; Lund FE. 2005. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 174(11):6781-90. [PubMed: 15905519]  [MGI Ref ID J:99038]

Harris DP; Goodrich S; Mohrs K; Mohrs M; Lund FE. 2005. Cutting edge: the development of IL-4-producing B cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells. J Immunol 175(11):7103-7. [PubMed: 16301612]  [MGI Ref ID J:122200]

Hartley SB; Crosbie J; Brink R; Kantor AB; Basten A; Goodnow CC. 1991. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353(6346):765-9. [PubMed: 1944535]  [MGI Ref ID J:78307]

Hartley SB; Goodnow CC. 1994. Censoring of self-reactive B cells with a range of receptor affinities in transgenic mice expressing heavy chains for a lysozyme-specific antibody. Int Immunol 6(9):1417-25. [PubMed: 7819151]  [MGI Ref ID J:132751]

Hermiston ML; Tan AL; Gupta VA; Majeti R; Weiss A. 2005. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 23(6):635-47. [PubMed: 16356861]  [MGI Ref ID J:113310]

Hippen KL; Schram BR; Tze LE; Pape KA; Jenkins MK; Behrens TW. 2005. In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance. J Immunol 175(2):909-16. [PubMed: 16002689]  [MGI Ref ID J:100671]

Hippen KL; Tze LE; Behrens TW. 2000. CD5 maintains tolerance in anergic B cells. J Exp Med 191(5):883-90. [PubMed: 10704468]  [MGI Ref ID J:124695]

Ho WY; Cooke MP; Goodnow CC; Davis MM. 1994. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J Exp Med 179(5):1539-49. [PubMed: 7909325]  [MGI Ref ID J:73608]

Kilmon MA; Rutan JA; Clarke SH; Vilen BJ. 2005. Low-affinity, Smith antigen-specific B cells are tolerized by dendritic cells and macrophages. J Immunol 175(1):37-41. [PubMed: 15972629]  [MGI Ref ID J:100598]

Kitaura Y; Jang IK; Wang Y; Han YC; Inazu T; Cadera EJ; Schlissel M; Hardy RR; Gu H. 2007. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 26(5):567-78. [PubMed: 17493844]  [MGI Ref ID J:123596]

Koralov SB; Muljo SA; Galler GR; Krek A; Chakraborty T; Kanellopoulou C; Jensen K; Cobb BS; Merkenschlager M; Rajewsky N; Rajewsky K. 2008. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132(5):860-74. [PubMed: 18329371]  [MGI Ref ID J:135783]

Kretschmer B; Luthje K; Guse AH; Ehrlich S; Koch-Nolte F; Haag F; Fleischer B; Breloer M. 2007. CD83 modulates B Cell function in vitro: increased IL-10 and reduced Ig secretion by CD83Tg B cells. PLoS ONE 2(1):e755. [PubMed: 17710154]  [MGI Ref ID J:129391]

Kumar KR; Li L; Yan M; Bhaskarabhatla M; Mobley AB; Nguyen C; Mooney JM; Schatzle JD; Wakeland EK; Mohan C. 2006. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 312(5780):1665-9. [PubMed: 16778059]  [MGI Ref ID J:109640]

Li DH; Tung JW; Tarner IH; Snow AL; Yukinari T; Ngernmaneepothong R; Martinez OM; Parnes JR. 2006. CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J Immunol 176(9):5321-8. [PubMed: 16621999]  [MGI Ref ID J:131658]

Lo CG; Xu Y; Proia RL; Cyster JG. 2005. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med 201(2):291-301. [PubMed: 15657295]  [MGI Ref ID J:95700]

Macaulay AE; DeKruyff RH; Umetsu DT. 1998. Antigen-primed T cells from B cell-deficient JHD mice fail to provide B cell help. J Immunol 160(4):1694-700. [PubMed: 9469426]  [MGI Ref ID J:111514]

Manderson AP; Quah B; Botto M; Goodnow CC; Walport MJ; Parish CR. 2006. A novel mechanism for complement activation at the surface of B cells following antigen binding. J Immunol 177(8):5155-62. [PubMed: 17015700]  [MGI Ref ID J:139451]

Mandik-Nayak L; Racz J; Sleckman BP; Allen PM. 2006. Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J Exp Med 203(8):1985-98. [PubMed: 16880262]  [MGI Ref ID J:124390]

McDonald KG; McDonough JS; Newberry RD. 2005. Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles. J Immunol 174(9):5720-8. [PubMed: 15843574]  [MGI Ref ID J:98463]

Merrell KT; Benschop RJ; Gauld SB; Aviszus K; Decote-Ricardo D; Wysocki LJ; Cambier JC. 2006. Identification of anergic B cells within a wild-type repertoire. Immunity 25(6):953-62. [PubMed: 17174121]  [MGI Ref ID J:116779]

Okada T; Miller MJ; Parker I; Krummel MF; Neighbors M; Hartley SB; O'Garra A; Cahalan MD; Cyster JG. 2005. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 3(6):e150. [PubMed: 15857154]  [MGI Ref ID J:99611]

Pathak S; Ma S; Trinh L; Lu R. 2008. A role for interferon regulatory factor 4 in receptor editing. Mol Cell Biol 28(8):2815-24. [PubMed: 18285461]  [MGI Ref ID J:133924]

Patterson HC; Kraus M; Kim YM; Ploegh H; Rajewsky K. 2006. The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Igalpha cytoplasmic domain. Immunity 25(1):55-65. [PubMed: 16860757]  [MGI Ref ID J:113407]

Phan TG; Amesbury M; Gardam S; Crosbie J; Hasbold J; Hodgkin PD; Basten A; Brink R. 2003. B cell receptor-independent stimuli trigger immunoglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J Exp Med 197(7):845-60. [PubMed: 12668643]  [MGI Ref ID J:132538]

Pluger EB; Boes M; Alfonso C; Schroter CJ; Kalbacher H; Ploegh HL; Driessen C. 2002. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol 32(2):467-76. [PubMed: 11813165]  [MGI Ref ID J:107213]

Quong MW; Harris DP; Swain SL; Murre C. 1999. E2A activity is induced during B-cell activation to promote immunoglobulin class switch recombination. EMBO J 18(22):6307-18. [PubMed: 10562543]  [MGI Ref ID J:118965]

Refaeli Y; Young RM; Turner BC; Duda J; Field KA; Bishop JM. 2008. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6(6):e152. [PubMed: 18578569]  [MGI Ref ID J:139351]

Reif K; Okkenhaug K; Sasaki T; Penninger JM; Vanhaesebroeck B; Cyster JG. 2004. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 173(4):2236-40. [PubMed: 15294934]  [MGI Ref ID J:92733]

Rivera A; Chen CC; Ron N; Dougherty JP; Ron Y. 2001. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 13(12):1583-93. [PubMed: 11717199]  [MGI Ref ID J:107395]

Roldan E; Fuxa M; Chong W; Martinez D; Novatchkova M; Busslinger M; Skok JA. 2005. Locus 'decontraction' and centromeric recruitment contribute to allelic exclusion of the immunoglobulin heavy-chain gene. Nat Immunol 6(1):31-41. [PubMed: 15580273]  [MGI Ref ID J:134531]

Roy V; Bonventi G; Cai Y; Macleod R; Wither JE. 2007. Immune mechanisms leading to abnormal B cell selection and activation in New Zealand Black mice. Eur J Immunol 37(9):2645-56. [PubMed: 17668901]  [MGI Ref ID J:124351]

Roy V; Chang NH; Cai Y; Bonventi G; Wither J. 2005. Aberrant IgM signaling promotes survival of transitional T1 B cells and prevents tolerance induction in lupus-prone New Zealand black mice. J Immunol 175(11):7363-71. [PubMed: 16301643]  [MGI Ref ID J:122135]

Schram BR; Tze LE; Ramsey LB; Liu J; Najera L; Vegoe AL; Hardy RR; Hippen KL; Farrar MA; Behrens TW. 2008. B cell receptor Basal signaling regulates antigen-induced Ig light chain rearrangements. J Immunol 180(7):4728-41. [PubMed: 18354197]  [MGI Ref ID J:133383]

Shimomura Y; Ogawa A; Kawada M; Sugimoto K; Mizoguchi E; Shi HN; Pillai S; Bhan AK; Mizoguchi A. 2008. A unique B2 B cell subset in the intestine. J Exp Med 205(6):1343-55. [PubMed: 18519649]  [MGI Ref ID J:137039]

Silveira PA; Chapman HD; Stolp J; Johnson E; Cox SL; Hunter K; Wicker LS; Serreze DV. 2006. Genes within the Idd5 and Idd9/11 Diabetes Susceptibility Loci Affect the Pathogenic Activity of B Cells in Nonobese Diabetic Mice. J Immunol 177(10):7033-41. [PubMed: 17082619]  [MGI Ref ID J:114754]

Silveira PA; Dombrowsky J; Johnson E; Chapman HD; Nemazee D; Serreze DV. 2004. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol 172(8):5086-94. [PubMed: 15067092]  [MGI Ref ID J:89156]

Silveira PA; Johnson E; Chapman HD; Bui T; Tisch RM; Serreze DV. 2002. The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol 32(12):3657-66. [PubMed: 12516557]  [MGI Ref ID J:80859]

Silver K; Ferry H; Crockford T; Cornall RJ. 2006. TLR4, TLR9 and MyD88 are not required for the positive selection of autoreactive B cells into the primary repertoire. Eur J Immunol 36(6):1404-12. [PubMed: 16703567]  [MGI Ref ID J:115059]

Skelsey ME; Mayhew E; Niederkorn JY. 2003. Splenic B cells act as antigen presenting cells for the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 44(12):5242-51. [PubMed: 14638723]  [MGI Ref ID J:107362]

Tsitoura DC; Yeung VP; DeKruyff RH; Umetsu DT. 2002. Critical role of B cells in the development of T cell tolerance to aeroallergens. Int Immunol 14(6):659-67. [PubMed: 12039917]  [MGI Ref ID J:133557]

Tze LE; Schram BR; Lam KP; Hogquist KA; Hippen KL; Liu J; Shinton SA; Otipoby KL; Rodine PR; Vegoe AL; Kraus M; Hardy RR; Schlissel MS; Rajewsky K; Behrens TW. 2005. Basal immunoglobulin signaling actively maintains developmental stage in immature B cells. PLoS Biol 3(3):e82. [PubMed: 15752064]  [MGI Ref ID J:133822]

Velazquez P; Wei B; McPherson M; Mendoza LM; Nguyen SL; Turovskaya O; Kronenberg M; Huang TT; Schrage M; Lobato LN; Fujiwara D; Brewer S; Arditi M; Cheng G; Sartor RB; Newberry RD; Braun J. 2008. Villous B cells of the small intestine are specialized for invariant NK T cell dependence. J Immunol 180(7):4629-38. [PubMed: 18354186]  [MGI Ref ID J:133099]

Weber M; Treanor B; Depoil D; Shinohara H; Harwood NE; Hikida M; Kurosaki T; Batista FD. 2008. Phospholipase C-gamma2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen. J Exp Med 205(4):853-68. [PubMed: 18362175]  [MGI Ref ID J:133999]

Wen R; Chen Y; Schuman J; Fu G; Yang S; Zhang W; Newman DK; Wang D. 2004. An important role of phospholipase Cgamma1 in pre-B-cell development and allelic exclusion. EMBO J 23(20):4007-17. [PubMed: 15372077]  [MGI Ref ID J:93280]

Winslow MM; Gallo EM; Neilson JR; Crabtree GR. 2006. The calcineurin phosphatase complex modulates immunogenic B cell responses. Immunity 24(2):141-52. [PubMed: 16473827]  [MGI Ref ID J:113318]

Wong MX; Hayball JD; Jackson DE. 2008. PECAM-1-regulated signalling thresholds control tolerance in anergic transgenic B-cells. Mol Immunol 45(6):1767-81. [PubMed: 17977600]  [MGI Ref ID J:131644]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           FGB27

Colony Maintenance

Breeding & HusbandryThe transgene is derived from BALB/c mice and has an IgHa allotype, while the recipient C57BL/6 mice have an IgHb allotype. Both light and heavy chain genes specific for hen egg lysozyme were injected into the B6 eggs. The transgene consists of Igk-C (kappa chain constant region) and rearranged Igh-6 (IgM) and Igh-5 (IgD) heavy chains specific for hen egg lysozyme (HEL). The donating investigator reports that the transgene integrated on Chromosome 17.
Mating SystemInbred x Hemizygote         (Female x Male)
Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations View International pricing
Weeks of AgePrice*GenderGenotypes Provided
Individual Mouse Price $232.00Female or MaleHemizygous for Tg(IghelMD4)4Ccg
Pairs /Price*Pair Genotype
$248.90C57BL/6J (000664) x Hemizygous for Tg(IghelMD4)4Ccg
*Price(s) in US dollars ($)

Additional Supply Details

Supply Notes

Pricing for International shipping destinations View USA Canada and Mexico pricing
Weeks of AgePrice*GenderGenotypes Provided
Individual Mouse Price $301.60Female or MaleHemizygous for Tg(IghelMD4)4Ccg
Pairs /Price*Pair Genotype
$323.60C57BL/6J (000664) x Hemizygous for Tg(IghelMD4)4Ccg
*Price(s) in US dollars ($)

Additional Supply Details

Supply Notes

Supply Details

Standard SupplyRepository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement.
Supply Notes

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions


See Terms of Use


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.


(3.2)